Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox

The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL patients continue to relapse, and sooner or later, most require subsequent lines of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Tadeusz, Janus, Agnieszka, Jamroziak, Krzysztof, Tiacci, Enrico, Kreitman, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269075/
https://www.ncbi.nlm.nih.gov/pubmed/34202156
http://dx.doi.org/10.3390/jcm10132800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269075/
https://www.ncbi.nlm.nih.gov/pubmed/34202156
http://dx.doi.org/10.3390/jcm10132800

Ejemplares similares